This segment focuses on the development, manufacturing, and commercialization of micro-invasive glaucoma surgery (MIGS) devices and related technologies. Research and development activities include ongoing innovation of the iStent platform, including the iStent inject and iStent infinite, as well as exploring new delivery methods and materials to enhance aqueous humor outflow. Technologies used include micro-scale device platforms and advanced biomaterials. The therapeutic area is primarily glaucoma, targeting patients with mild-to-moderate open-angle glaucoma. The patient impact is significant, offering minimally invasive solutions to reduce intraocular pressure and potentially reduce or eliminate the need for medication. Market positioning is strong, as Glaukos was a pioneer in MIGS. Future opportunities include expanding the product portfolio and geographic reach. Clinical trials and regulatory approvals are crucial for market access and product validation. Partnerships with ophthalmologists and distributors are key to commercial success.

This segment is dedicated to developing and commercializing products for corneal disorders. Research and development efforts focus on technologies like corneal cross-linking (CXL) and other treatments for conditions such as keratoconus. Technologies and methodologies include UV light-based therapies and advanced diagnostic tools. The therapeutic area is corneal health, addressing conditions that affect the cornea's structure and function. Patient impact involves improving vision and quality of life for individuals with corneal diseases. Market positioning is based on providing innovative solutions for corneal disorders. Future opportunities include expanding the product line and exploring new applications of CXL technology. Regulatory approvals and clinical trials are essential for market entry and product validation. Partnerships with ophthalmologists and clinics are important for market penetration.

This segment focuses on the development of novel therapies for retinal diseases. Research and development activities include exploring new drug delivery systems and therapeutic approaches for conditions like age-related macular degeneration (AMD) and diabetic retinopathy. Technologies and methodologies include micro-scale device platforms and sustained-release drug formulations. The therapeutic area is retinal diseases, targeting conditions that affect the retina and impact vision. Patient impact involves preserving and improving vision for individuals with retinal disorders. Market positioning is based on providing innovative solutions for retinal diseases. Future opportunities include expanding the product line and exploring new applications of drug delivery technology. Regulatory approvals and clinical trials are essential for market entry and product validation. Partnerships with ophthalmologists and clinics are important for market penetration.